



GOODBODY
HEALTH

Know More. Live Better.

Introduction to Goodbody Health

Know More.
Live Better.

To provide 'frontline' healthcare services in the local community and enable customers to manage their health care digitally.

Products

- Distributor and retailer of diagnostic, wellness products and services.
- COVID-19 travel testing - PCR and Antigen tests
- COVID-19 Antibody blood tests
- CBD
- Our growing range of wellness & diagnostic tests include:



Cholesterol Levels



Well Woman & Man tests



Thyroid Function



And much more

Digital



Virtual GP referral pathway



Health assessments



In-pharmacy apps

Support



In-house experienced



management team



Marketing support



Business Development Managers



Customer service centre



Phlebotomy Training

Over
140
Clinics nationwide

Over
100K
Covid tests



Who we work with



Introduction to Goodbody Health

Offering PCR and Health Diagnostic testing products to drive footfall and revenue into independent pharmacies.



Achieving 4.8-star average Google ratings.



Blueprint established with rapidly expanding network of products and services.



Supporting the NHS to operate first-touch screening services via pharmacies.



Established management team with proven track record.



A number of technology led testing devices and key partners.




We develop close relationships to drive footfall and much needed revenue for independent pharmacies.


Introduction to Goodbody Health

- Established infrastructure; (i) head office housing the operational team, (ii) a specialist ISO accredited UK laboratory (iii) an in-house manufacturing, warehouse, and fulfilment facility, (iv) a polish CBD manufacturing and testing facility and (v) retail units in Bristol and Bath.
- Blueprint established with rapidly expanding network of products and services.
- Close relationships within the local community clinics, drives footfall and subsequently much needed revenue for independent pharmacies.

Cumulative Number of Clinics Set up in 2021



Cumulative Payments to Pharmacies in 2021



Goodbody Health Strategy

combined with Technology Pipeline fully supports NHS Long Term Plan

NHS Long Term Plan

The need for radical investment and reform of diagnostic services was recognised at the time the NHS Long Term Plan was published in 2019. The Covid-19 pandemic has further amplified the need for radical change in the provision of diagnostic services.

- The three main deliverables of the NHS plan are:
 - making sure everyone gets the best start in life,
 - delivering world class care for major health problems and
 - supporting people to age well
- Our Clinic proposition supports all three ambitions but in particular testing for diagnosis symptoms
- The NHS plan sets out that there is a need to give people more control over their own health, using community services such as providers like Goodbody Clinics
- Funding to achieve these ambitions will be increased for community care by £4.5bn
- Community phlebotomy services should be improved, so that all patients can have blood samples taken close to their homes, at least six days a week, without needing to come to hospitals or GPs
- The NHS is looking carefully at which services can be easily undertaken by pharmacies rather than GP surgeries. The 2021 flu programme demonstrates a bigger involvement with pharmacies. This will be followed by minor injuries clinics. The key to this will be the development of the Community Pharmacy Consultation Service, which will allow the NHS to commission an increasing range of services from pharmacy in support of the new Integrated Services model in the NHS.

Roll Out

Scale up the proven success model using the existing blue print.

Distribution Network of Over 2,000 Community Diagnostic Hubs by 2024 to create a national footprint.

Transfer of key services from the local GP practices into local diagnostic hubs.

Disrupt the current courier to lab model with local modern technology.

Routes to market including local clinics, mobile, online, business to business and public organisations such as schools.

Operational model driving people into diagnostic hubs to use assessment tools and provide targeted testing **with immediate results delivery.**

Develop the in-house phlebotomy school to provide training for clinic staff.

Exclusive contracts with Pharmacy / Clinics.

Technology Deployed

The R&D pipeline is very flexible reflecting the platform nature of the technology. Its advantage is that it can do multiple tests simultaneously.

A research contract with a specific customer could be performed in the laboratory immediately and then transferred to the device.

e.g. Abbott and Duplex: Retailer/distributor of technology and diagnostics.



The Problem

The world is faced with growing health epidemics and challenges, which puts traditional health services under unprecedented stress.

*230 million biochemistry and 47 million haematology investigations were requested in 2014-15, at an estimated cost of **£3bn for the NHS**.

*Department of Health for England

Even with a robust vaccination program, living with COVID-19 will require significantly more comprehensive disease surveillance of the UK population, combined with flu and other viral mutations.

Significant diagnostic delays in the NHS.

The national testing infrastructure that provides a quantitative picture of individual and collective immunity is urgently required.

What We Are Doing

Improving connectivity and digitisation across all aspects of diagnostics prioritised to drive efficiency, deliver seamless care across traditional boundaries and facilitate remote reporting.



Current Goodbody

Goodbody Health is disrupting the 'old model' of courier to laboratory style testing.

Goodbody Health partners with like minded independent pharmacies which, when combined with our marketing expertise, digitisation skills, commercialisation with cutting edge technology is a powerful combination.

Current Pharmacies

Pharmacies are professionals with strong medical knowledge and experience.

Independent pharmacies are considered the community medical team trusted by patients for advice and help. Independent Pharmacies have lost funding and many are struggling to cover costs reducing the opportunity to invest in the latest technology.

Individual pharmacies have limited resources to apply through traditional commissioning routes to expand their services.

Goodbody Health Strategy



By placing the customer at the heart of everything we do, we offer the pharmacy team bespoke training to give them skills to help the local community. Future proofing through patents and the ability to adapt for tests based on community led needs.



Positively caring – with genuine interest in the wellbeing of our customers to provide relevant products.



Serious about quality – ensuring compliance and regulation with undertaking CQC accreditation.

Support NHS long term plan

Provide 'frontline' healthcare services in the local community partnering with independent pharmacies.


Implement advanced technology to disrupt the existing inefficient model.

Enable customers to manage their health care digitally.

Provide local and remote solutions to the three distinct groups - 'wellness inquirers', 'diagnostic concerns' and 'existing conditions'.

Networked together via the Cloud, Goodbody Health combined with advanced technology and app-based care pathways will provide many more healthcare professionals and patients with newly accessible ways to diagnose and manage their health.

Market Size




Market Size

Existing independent market is over half of the pharmacies in the UK.

2,000 clinics less than 30% of the independent market.


Clinic Rollout

Quarterly projected number of Community Diagnostic Hubs




PCR to Bloods

Projected Number of Tests



Route to market



Audiences

The Goodbody product range delivers younger audiences through the door of the pharmacy.

Tapping into their disposable income of the audiences that are worried about their health and wellness.

Creating a new revenue stream into the pharmacy.

The perfect marriage of marketing, expertise and science to support the NHS and develop testing for a growing need.

The 'Post Covid' Inquisitor

'Know more, live more'



Lives and active and busy life



Fairly affluent and happy to spend money on retaining her health



Contracted Covid-19 and from that became anxious about retaining her health and any on-going illnesses caused by Covid



A believer in pre-empting any potential concerns and adjust her lifestyle accordingly



Needs on-going reassurance from a 3rd party



Would choose to receive instant results rather than increase her stress levels



Likes to have a dialogue with someone on-going for her health



The 'Diagnostic Wellness' Customer

'Know more *faster*, live better'



Sporty and has a good social life



Time poor but cash rich



Interested in maintaining and increasing his health




Follows wellness and health trends on social media, tracks new product launches and excited about innovations, (and willing to pay for them)



Feels that he has become a little sluggish and drowsy and wants to know what changes he can make to remedy this



Happy to consider non-prescriptive solutions such as CBD.



Managing a Chronic Condition

‘Take control-manage my health’



Leads a busy life and a young family



Has type 2 diabetes



Difficulty in getting GP appointments and her time is precious. Measurement can be part of intervention to support self-management



Often at the pharmacy for vaccinations for the children or picking up essential medications



Wants to have a rapport with someone who quickly understands her needs



Needs instant results and a local led solution to have a shared agenda



Knowledgeable about the condition and what solutions there are on the market with the availability to evaluate interventions



Goodbody Marketing Strategy



Hot topic- elevating our position with the health topics raised in the business and consumer domain.



Test clinics- taking the established blueprint to phase into the blood testing to refine operations and marketing to continue to roll out further at a national level.



Routes to market – Distribution via independent pharmacies, other 3rd party affiliations, mobile clinics and webstore.



Customer pathway – initial ‘click and bait’ offers to hook customers and start on-going relationship through our customer pathways.

CONSUMER

Off the shelf solutions- Creating product packages that offer customer solutions to generate revenue into his pharmacy.

Interactive technologies -Driving footfall and engagement-App, in clinic interactive wellness survey.

BUSINESS TO BUSINESS

Business Packages – To sell as an employee benefit into the HR department of local trade within a radius of their local pharmacy.

Employee Package - Creating packages for the HR department to offer as a benefit to their employees.

DISTRIBUTION & STAKEHOLDER COMMS.

On-boarding and retention of independent pharmacies.

Stakeholder – on-going communications as part of the journey.

Consumer Marketing Tactical Plan



LOCAL-driving footfall at a local level:

- **Digital** – PPC, Google AdWords-paid and building organic positioning.
- **Social**-organic and paid Instagram, Facebook, Pinterest, YouTube.
- **SEO**- targeting keywords.
- **Programmatic**- with specific criteria.
- **OOH** –within a radius to the pharmacy
- **Database**- over 100K on database.
- **Loyalty** – member get member
- **Influencers** – local and national distribution.
- **PR**- promoting new technologies and services within the clinics.

NATIONAL– driving footfall and brand awareness:

- **Webstore** – new webstore with stronger focus on bloods
- **Radio** – local to roll out national.
- **TV/VOD**- local to roll out national.

TACTICAL



Why work with Goodbody Health?

The result is higher revenue and customer traffic for the Pharmacy

-Goodbody takes the financial risk.

Goodbody drives footfall to your pharmacy through our instigated local level marketing.

-Goodbody provides free phlebotomy training for a Pharmacy employee to enable a full venous blood draw.

-Soft sell that does not take up the staff's time

-Goodbody Customer Support team to back up services provided.

-A range of constantly developing products and services.

-Couriers, external laboratories and PPE managed and funded by Goodbody.

-Goodbody provides diagnostic equipment to facilitate rapid on-site testing and some results delivered in minutes.


-Commission paid to pharmacists.

-Part of a team without losing your independence.

-Goodbody works closely with the Pharmacy creating 4.8* Google reviews.

-A wealth of expertise at Goodbody providing knowledge and support.

-Planned 2,000 clinics by 2024.



Your Goodbody blood
test kit has arrived...










www.goodbodyclinic.com

"We have had an excellent relationship working with the Goodbody clinic. Ever so helpful, supportive and the new innovative ideas always keep us feeling excited. Would highly recommend them!"

What you don't know, might be harming you!



Know More. Live Better.

 <p>Impotence Profile</p>	 <p>Testosterone</p>	 <p>Sports Performance</p>
 <p>Iron Status</p>	 <p>Advanced Well Woman/Man</p>	 <p>Cholesterol</p>
 <p>Pre-Diabetes</p>	 <p>Sexual Health</p>	 <p>Liver & Kidney Function</p>

What you don't know, might be harming you!

Know More. Live Better.



Fertility &
Hormones



Thyroid
Function



Heart
Health



Prostate
Health



Tiredness &
Fatigue



Vitamin
Profile



Covid-19
Antibodies



Anti-Mullerian
Hormone



UK Allergy
Profile

Our Goodbody Health Pharmacists

Experienced, knowledgeable and trusted by their customers.



Average commission from first month

True averages based on all our existing pharmacy partners



By contrast, NHS doctors do not have the time to provide additional services and value pharmacists providing this service in the community.



UK pharmacists themselves are under intense commercial pressure, with the reduction in Government subsidy, low margin on each prescription and competition from digital repeat prescription businesses.



Pharmacy funding for 2021/22 remains unchanged at £2.59bn, a cut in real terms.



Seeking ways to enhance their income through the provision of additional paid-for services.



Looking to optimise modern healthcare services that utilise their expertise, client relationships, convenient locations using TECHNOLOGY.



They see an expanded role for their profession to play as part of a total healthcare team.



With Goodbody they can expand their role and income.



BRISTOL PHARMACY

Best in Class Wellness Solutions

Providing a complete wellness solution.

Testing and research of Attomarker technologies working alongside Exeter University.

Working with our in-house phlebotomists and staff to help tailor our services and training to help our local community.

Offering customers virtual medical consultations for the results of their wellness blood tests.

Best in Class Wellness Solutions



Working in partnership to offer a complete wellness solution at a local community level.

Provide a bespoke training package for the pharmacy staff to include phlebotomy and training for vulnerable customers within the local area.

“Since working with Goodbody we have seen a significant increase in footfall into the pharmacy. It’s rewarding to see how we are fulfilling a real need in the local community”.

George Wickham , Luxtons Pharmacy,
Exeter



Mobile solutions also offered in locations, equipped with a trained phlebotomist.

Jonny Bentley

1 review



Very good experience. Very fast. Friendly attendants. Clean space. Results turned up in email about 3am the next day. Also, excellent price. Was stressed before my flight back to Spain but this process was very user friendly. Would recommend to anybody in the area searching this service.

In-House Expertise



In-house experienced team from agency and client-side backgrounds with **expertise for all marketing communication routes.**

Creating a **birth to death life stage marketing programme and products** using CRM, data and technologies.

Based on data and technologies drive seasonal products and marketing programmes.

In-house digital expertise and the ability to use data to drive and refine activities.

Good foundation of understanding the pharmacies, their needs and the needs of their customers. Maximising our in-house analysts to data mine and refine programmes according to findings.

The team develop **customer pathways** to ensure that the experience works for the Community Hub and consumer. A plan of testing and refining is implemented to develop maximum **returns on investment and reducing the cost per acquisition.**

In-house dedicated quality and compliance team. Specialist experts in the required fields.

CQC accreditation underway.

ISO17025 testing laboratory certified.

ISO22000 food manufacturing certified.

HACCP accredited production and distribution areas.

Quality control - Where possible, operations and training are held and managed in-house for consistency of quality.

We apply **effective problem identification and problem-solving techniques.**, strengthen customer service through a focus on continuous improvement.

Environmental, Social, Governance (ESG)

We deliver products and services to our stakeholders that support, impact and underpin socially responsible themes.

Climate action: Becoming a net zero business within a low carbon economy.

Diversity and inclusion: Accelerating progress to improve representation and diverse talent pipelines.

Empowering colleagues and our communities: Sustaining a skilled workforce today and for the future, continuing to prioritise colleague health and wellbeing, and taking action to help and collaborate with communities in need.

Supporting and connecting our clients: Being clear and

transparent about how we can help clients to improve their sustainability performance through an ESG-centric approach.

Acting with integrity in everything that we do: Taking ownership and holding ourselves accountable for the way we do business.

Building trust and increasing transparency: Enhancing the credibility of our own ESG disclosure, consistent with our purpose of delivering positive outcomes with our colleagues, clients and communities.

Goodbody Health Exec Team Bios



**Jeremy Thomas,
Founder & Chairman
of Goodbody Health**

Jeremy is an entrepreneur with a successful track record in the telecommunication, e-learning and consumer finance industries. After being involved at senior level in The Carphone Group Plc before it was sold, Jeremy went on to create and list PNC Telecom Plc. In 2001 Jeremy co-founded TMTI Ltd. TMTI Ltd is a profitable technical support business which works with major brands in enhancing the customer experience. Jeremy founded George Banco Ltd in 2013, a consumer finance business, which was later sold to Non-Standard Finance Plc. Jeremy's other business interests include Carbon Managers Ltd, an environmental services consultancy company. More recently, Jeremy founded the Sativa Group in 2018 and was its first CEO. After a period as a non-executive and then taking a break from the company, Jeremy has returned as the Executive Chairman to lead the board.



**Marc Howells, Chief
Executive Officer,
Goodbody Health**

Marc has a 36-year track record of high performing results and achievements across the financial services industry. His extensive career includes senior roles in Citibank and Barclaycard before heading up a number of SME financial services companies as CEO or Managing Director. He has significant experience in developing and operating industry leading management teams with best-in-class employee retention and value. His extensive financial services industry experience includes in depth experience on; integrations, mergers, joint ventures, acquisitions, restructuring and start-ups. He has built up geographical and cultural expertise across China, Europe, U.S.A. and South Africa.



**Anne Tew,
Chief Financial Office
and Company Secretary
of Goodbody Health**

Anne is an experienced Accountant, Corporate Secretary and professional business strategist and mentor with over 30 years' experience across a range of industries including the NHS, testing laboratories, manufacturing and farming. She has successfully led projects to achieve business turnaround, restructuring, growth and development. Anne has worked as an Executive and Non-Executive Director, including in the NHS, as well as advising board members in financial and governance matters as the Corporate Secretary or as an external consultant.



**George Thomas, Director
of Goodbody Health and
Managing Director of
Goodbody Wellness**

George is a successful entrepreneur who has established an eclectic mix of businesses across an array of industries including Tech, Finance, Environmental and Wellness. George was a founding director and board member of George Banco Ltd, a consumer finance business, which was later sold to Non-Standard Finance Plc. George is the Managing Director of Goodbody Botanicals Ltd, the main operating subsidiary of the Sativa Wellness Group through which he has successfully introduced a range of wellness products and services.


Goodbody Health Exec Team Bios



**Clive Standish,
Non-Executive Director,
Goodbody Health**

Clive Standish's professional career began with N M Rothschild & Sons Ltd in London. In 1979 he was appointed a partner with Dominguez & Barry in Australia and became a member of the Melbourne Stock Exchange in 1980. He was the founding Executive Director at Dominguez Barry Samuel Montagu Limited and subsequently Head of Capital Markets and Managing Director until 1991 and then CEO of SBC and Warburg Dillon Read Australia.

In 1998, Clive Standish was appointed Chairman and CEO for Asia Pacific UBS AG and member of the Managing Board and subsequently member of the Group Executive Board. In 2003 he moved to Zurich as Group Chief Financial Officer UBS AG until 2007 when he retired from the Board of UBS AG.



**Mark Blower, Non-
Executive Director,
Goodbody Health**

Mark Blower is an experienced finance professional, having spent the last 20 years actively overseeing the financial performance of over 70 UK SME's, with a particular focus on raising debt and private equity. He began his career in 1996 at the Investment Banking division of a large UK bank, before joining NM Rothschild in 2000. He then ran a highly successful leveraged debt team for another UK lending institution for five years before starting his Private Equity career in 2010. During his career to-date he has held a number of board positions, across a variety of sectors.



**Professor Clive Page,
Scientific Advisory
Committee Chair OBE,
BSc, PhD**

Clive Page is Professor of Pharmacology, King's College London and Director of the Sackler Institute of Pulmonary Pharmacology, King's College London, and he has published over 300 scientific papers and book chapters. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non-Executive Director of PreP Biopharma and the Non-Executive Chairman of the Board of EpiEndo, as well as being a Trustee of the Fraunhofer Institute of Toxicology and Experimental Medicine in Hannover. He is a Fellow of the Royal Society of Biology and an Honorary Fellow of the British Pharmacological Society. Clive was awarded an OBE for "Services to Pharmacology" in 2017.



**Ian Strachan,
Scientific Advisory
Committee member and
Chair the Pharmacy
Focus Group**

I started out working as a Forensic scientist at the home office forensic science laboratories Aldermaston Reading Berks. I worked in the chemistry division which focused on crimes against the person with the police liaison teams. I was sponsored by the Home Office to do pharmacy in 1992-1985. After graduating in pharmacy, I became a manager of Boots small stores and worked for many independents between 1986 and most of my professional lifetime. I represented the interests of community pharmacy since 2000 as a member of the board of management to the National pharmacy association since 2000 becoming its longest serving chairman in 2014-2018. During this period, it is widely acknowledged that my leadership and the board I led improved the outcomes for thousands of pharmacy owners and their teams.

Goodbody Health Exec Team Bios



Dr Jamie Brosch
MA MBBChir
DRCOG RCGP (91)
Scientific Advisory
Committee Member

A former GP Principal and founding Medical Director of Medvivo, a successful provider of Out of Hours and Urgent Care Services and the Digital Health Service, Doctorlink

As a GP, I had a wide range of clinical interests, including Urgent and Emergency Care, Musculoskeletal Medicine and Mental Health and Addiction.

I only continue with a small clinical portfolio but I maintain a keen interest in the full range of health and medical care.

I'm at my happiest, outdoors, cycling, walking, fishing or working my dogs.

I'm a passionate advocate for active lifestyles, for maintaining good physical and mental health and well-being.



Nick Clarkson,
Chief Scientific Officer,
Phytovista Laboratories

Nick started his career with a scholarship at Zeneca Agrochemicals working as a soil scientist, before moving to a position in food testing, specifically looking at adulteration in foods and drinks. After gaining his degree in applied chemistry, he went on to work in medicines development at AstraZeneca. After this he moved into a commercial role with a scientific instrument manufacturer, then at the beginning of 2018 established PhytoVista laboratories. In April 2021 the laboratory was granted accreditation to ISO17025:2017 by the United Kingdom Accreditation Service.



Lily Paduraru,
Group Quality Manager,
Goodbody Health (PHD)

Lily is an experienced Food Scientist in Research and Development in both academic and industry settings. She has been involved in Quality Control and Quality Assurance of food and cosmetic products as well as implementing and maintaining the Quality Management System in analytical laboratories. She has implemented and maintained the Quality Management System at Goodbody Health in accordance with ISO 17025 and ISO 9001 standards and helped to devise and establish related company procedures, standards and specifications. Lily has a Doctor of Philosophy (PhD) in Food Science and Environmental Chemistry



Emily Critchley,
Group Head of HR,
Goodbody Health

Emily is a highly experienced, strategic and operationally focused Human Resources leader. With a successful career across a broad range of businesses, Emily brings a passion around Human Resources and the transformative impact that the right People combined with the right strategy can have on the success of an organisation. Her professional experiences include executive level management, strategic program management, training/employee development, resource and budget forecasting, organisational development and employee relations.. Emily also brings significant operational and management experience across a range of industries from building teams in start-ups to managing multi-site commercial enterprises.

Goodbody Health Exec Team Bios



**Julia Edwards,
Group Head of
Marketing, Goodbody
Health**

Julia has a 30-year track record working in 'through the line' marketing. She has experience within marketing agencies and in-house client side, to manage brands including Whitbread, Aptamil Healthcare, Red Bull, Pernod Richard and the Gala Group. Julia's career took her to become a Board Member of WWAV Rapp Collins and managing marketing budgets of over £10 million. Her experience led to working in small and large establishments and managing in-house marketing teams and agencies alike. Her experience heavily focused on business to consumer using above and below the line communications to acquire and retain customers.



**Piotr Bawic,
QA and Laboratory
Manager -Poland**

Piotr achieved a MSC in Pharmacy from the Medical University of Lublin, Poland in 2008 where he began his doctorate in 2011. Working 5 years in local pharmacies and finally became the owner / co-owner of 3 pharmacies in Kielce, Poland for over 10 years. From 2014 to 2018 Piotr was Vice President at NetPharma, a company that brings together local pharmacists and acts as an intermediary in the trade of drugs and medicinal products. During this time, he created a common brand for 30 pharmacies, purchasing strategies and creating a proper sales structure with marketing to patients. Piotr also has extensive knowledge in the field of clinical drug testing, and he holds a certificate of completion of CRA SQL IQVIA in 2017.



**Mateusz Manager
– Production Manager -
Poland**

Mateusz is the Production Manager for the Extraction plant in Poland. He has been a part of Olimax since the beginning of the company, as he is the son of one of co-founders of the enterprise. His knowledge of hemp industry in Poland is very extensive. He has many contacts in the industry and has many years of experience in farming and cultivating hemp. Mateusz set up the extraction facility and is currently managing the Polish production process to include the production of new CBD end products. His personal interests in both the vehicles industry and hemp industry encourage him to develop innovative improvements into farming equipment.



**Krzysztof Wojtanowski
Head of Regulatory
Affairs Poland**

Krzysztof holds a Master Diploma and a PhD in Pharmacy and Pharmaceutical Science from the Medical University in Lublin, Department of Pharmacognosy. After completion of his PhD degree, he started work at the Department of Pharmacognosy with the Medicinal Plant Unit as a scientific specialist. He started his professional carrier as a pharmacist in 2008, working in several pharmacies in Poland and is now Head of the Hospital Pharmacy Department at the Ophthalmology Clinic "Okulistyka" in Bychawa, Poland responsible for drug management in clinics. Krzysztof has been working for Goodbody Health since 2019 and is also responsible for HACCP and THC license compliance.



GOODBODY
HEALTH

Know More. Live Better.

Disclaimer

- This presentation (“Presentation”) has been prepared by Goodbody Health Inc. (“Goodbody” or the “Company”) solely for purposes of providing introductory information on the Company and its projects and prospects. This Presentation should not be considered as the giving of investment advice by the Company or any persons, including to any of its shareholders, officers or advisers. If you are in any doubt about the contents of this Presentation or the action you should take, you should consult an independent adviser authorised to render such advice.
- This Presentation has not been independently verified and is subject to material updating, revision and further amendments without notice. The Presentation does not purport to contain all information that an investor in or creditor to the Company may wish to receive for the purposes of assessment or valuation and is not intended to form the basis of any investment or financial decision.
- While the information contained herein has been prepared in good faith, neither the Company nor its shareholders, directors, officers, agents, employees, or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to the achievement or reasonableness of future projections, management targets, estimates, prospects or returns contained in this presentation, or in relation to the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any investor (all such information being referred to as “Information”).
- So far as permitted by law, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability in respect of, the accuracy, reliability or completeness of the Information or for any loss, howsoever arising from the use of this Presentation. In furnishing this Presentation, the Company does not undertake any obligation to provide any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation contains certain statements which may constitute forward-looking statements. All statements in this Presentation, other than statements of historical facts, that address future activities and events of developments that the Company expects, are forward-looking statements. Although the Company believes that the expectations reflected in these statements are based on reasonable assumptions, such statements are only predictions and are subject to inherent risks and uncertainties and changes in the underlying assumptions which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.
- The Company will not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this Presentation, except as required by law or by any appropriate regulatory authority. Nothing in this Presentation or in documents referred to in it should be considered as a profit forecast. Past performance of the Company or its shares cannot be relied on as a guide to future performance.
- This Presentation does not constitute, or form part of or contain any offer or invitation to sell or issue, or any offer to subscribe for, underwrite or otherwise acquire, or dispose of, any securities in the Company in any jurisdiction and is directed at, and is only for distribution in the United Kingdom to persons reasonably believed to fall within Article 19 (Investment professionals) or Article 49 (High net worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) or to whom this Presentation may otherwise lawfully be distributed.
- Neither this Presentation nor any part of or copy of it may be taken or transmitted, directly or indirectly, into the United States of America or Canada or distributed or re-distributed directly or indirectly, in the United States of America, its territories or possessions, or Canada, or to any resident thereof except in compliance with applicable securities laws. Any failure to comply with these restrictions may constitute a violation of applicable U.S. or Canadian securities laws. This Presentation and the information contained herein do not constitute an offer of securities for sale in the United States. By accepting this Presentation, the recipient represents and warrants that it is a person to whom this Presentation may be delivered or distributed without a violation of the laws of any relevant jurisdiction. This Presentation is not to be disclosed to any other person or used for any other purpose and any other person who receives this Presentation should not rely or act upon it.
- The delivery or distribution of this Presentation in or to persons in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.
- By attending a meeting where this Presentation is made or distributed, or by reading the Presentation slides, you agree to be bound by these provisions.